Lakshmi Harinath

Lakshmi Harinath

Auto-generated profile, based on publicly available information

Lakshmi Harinath

Department of Pathology University of Pittsburgh Medical Centre Pittsburgh Pennsylvania USA

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 June 2025 in Cancer Cytopathology
Verified
Journal Article
Open access
EEEsther Elishaev
Esther Elishaev
LHLakshmi Harinath
Lakshmi Harinath
YYYuhong Ye
Yuhong Ye
JMJonee Matsko
Jonee Matsko
ACAmy Colaizzi
Amy Colaizzi
CZChengquan Zhao
Chengquan Zhao
Background: Medical technologies powered by artificial intelligence are quickly transforming into practical solutions by rapidly leveraging massive amounts of data processed via deep learning algorithms. There is a necessity to validate these innovative tools when integrated into clinical practice.Methods: This study evaluated the performance of the Hologic Genius Digital Diagnostics System (HGDDS) with a cohort of 890 previously reviewed and diagnosed ThinPrep Papanicolaou (Pap) tests with the intent to deploy this system for routine clinical use. The study included all diagnostic categories of The Bethesda System, with follow‐up tissue sampling performed within 6 months of abnormal Pap test results to serve as the ground truth.Results: The HGDDS demonstrated excellent performance in detecting significant Pap test findings, with close to 100% sensitivity (98.2%–100%) for cases classified as atypical squamous cells of undetermined significance and above within a 95% confidence interval and a high negative predictive value (92.4%–100%).Conclusions: The HGDDS streamlined workflow, reduced manual workload, and functioned as a stand‐alone system.

5 November 2024 in Cancer Cytopathology
Verified
Journal Article
Open access
LHLakshmi Harinath
Lakshmi Harinath
EEEsther Elishaev
Esther Elishaev
YYYuhong Ye
Yuhong Ye
JMJonee Matsko
Jonee Matsko
ACAmy Colaizzi
Amy Colaizzi
CZChengquan Zhao
Chengquan Zhao
Background: Artificial intelligence (AI)–based systems are transforming cytopathology practice. The aim of this study was to evaluate the sensitivity of high‐grade squamous intraepithelial lesion (HSIL) Papanicolaou (Pap) diagnosis assisted by the Hologic Genius Digital Diagnostics System (GDDS).Methods: A validation study was performed with 890 ThinPrep Pap tests with the GDDS independently. From this set, a subset of 183 cases originally interpreted as HSIL confirmed histologically were included in this study. The sensitivity for detecting HSIL by three cytopathologists was calculated.Results: Most HSIL cases were classified as atypical glandular cell/atypical squamous cell–high grade not excluded (AGC/ASC‐H) and above by all cytopathologists. Of these cases, 11.5% were classified as low‐grade squamous intraepithelial lesion (LSIL) by pathologist A (P‐A), 6% by pathologist B (P‐B), and 5.5% by pathologist C (P‐C); 3.8%, 2.7%, and 1.6% of these cases were classified as atypical squamous cell of unknown significance (ASC‐US) by P‐A, P‐B, and P‐C, respectively. The sensitivity for detection of cervical intraepithelial neoplasia 2 and above (CIN2+) lesions was 100% if ASC‐US and above (ASC‐US+) abnormalities were counted among all three pathologists. The sensitivity for detection of CIN2+ lesions was 84.7%, 91.3%, and 92.9% by P‐A, P‐B, and P‐C, respectively, for ASC‐H and above abnormalities. The Kendall W coefficient was 0.722, which indicated strong agreement between all pathologists.Conclusions: New‐generation AI‐assisted Pap test screening systems such as the GDDS have the potential to transform cytology practice. In this study, the GDDS aided in interpreting HSIL in ThinPrep Pap tests, with good sensitivity and agreement between the pathologists who interacted with this system.

18 January 2025 in Journal of the American Society of Cytopathology
Verified
Journal Article
Closed access
LHLakshmi Harinath
Lakshmi Harinath
EEEsther Elishaev
Esther Elishaev
YYYuhong Ye
Yuhong Ye
JMJonee Matsko
Jonee Matsko
ACAmy Colaizzi
Amy Colaizzi
CZChengquan Zhao
Chengquan Zhao

7 April 2023 in Journal of the American Society of Cytopathology
Verified
Journal Article
Closed access
TJTerri E. Jones
Terri E. Jones
JMJonee Matsko
Jonee Matsko
EEEsther Elishaev
Esther Elishaev
BCBeth Z. Clark
Beth Z. Clark
GCGloria Carter
Gloria Carter
CZChengquan Zhao
Chengquan Zhao

8 July 2025 in Acta Cytologica
Verified
Journal Article
Closed access
LHLakshmi Harinath
Lakshmi Harinath
XBXinru Bai
Xinru Bai
JMJeremy Minkowitz
Jeremy Minkowitz
XZXianxu Zeng
Xianxu Zeng
SHSarah Harrington
Sarah Harrington
LPLiron Pantanowitz
Liron Pantanowitz
Background: Cervical cancer is the fourth most common cancer in women globally with highest incidence and mortality identified in less developed and medically underserved areas in the world. The diminishing cytology workforce, unavailability of expert consultation, and the high volume of Pap tests needing manual screening are the main reasons for exploring innovative solutions to help mitigate the negative effects resulting from the dearth of timely cervical cancer screening in certain population groups. Summary: Developments in whole slide imaging and artificial intelligence (AI) have enabled the emergence of new computer-assisted systems that have the potential for transforming traditional cytopathology practice. However, AI-based systems are relatively new with limited published data on their validation and clinical utility in clinical practice. Our article aims to increase awareness of the availability of such systems, explores the history and development of AI-assisted screening platforms for Pap tests, compares the performance characteristics of various systems, elaborates on technical challenges associated with conducting clinical trials employing this technology, and discusses considerations around deploying such systems in routine cytopathology practice. Key Message: Revolutionary AI-based systems are being developed and utilized in cytopathology practice to screen Pap tests. Some of these systems have good performance characteristics and provide opportunities to combat various issues such as workload and standardization faced by cytology laboratories globally. However, judicious review of these systems using evidence-based studies is imperative to promote widespread adoption and maintain high-quality standards for patient safety.

14 May 2025 in Journal of the American Society of Cytopathology
Verified
Journal Article
Closed access
TJTerri E. Jones
Terri E. Jones
XZXianxu Zeng
Xianxu Zeng
JMJonee Matsko
Jonee Matsko
LHLakshmi Harinath
Lakshmi Harinath
EEEsther Elishaev
Esther Elishaev
CZChengquan Zhao
Chengquan Zhao